Journal of Cerebral Blood Flow & Metabolism (2015), 1–8 © 2015 ISCBFM All rights reserved 0271-678X/15 $32.00 www.jcbfm.com

REVIEW ARTICLE

Longitudinal change of small-vessel disease–related brain abnormalities Reinhold Schmidt, Stephan Seiler and Marisa Loitfelder Knowledge about the longitudinal change of cerebral small-vessel disease–related magnetic resonance imaging abnormalities increases our pathophysiologic understanding of cerebral microangiopathy. The change of specific lesion types may also serve as secondary surrogate endpoint in clinical trials. A surrogate endpoint needs to progress fast enough to allow monitoring of treatment effects within a reasonable time period, and change of the brain abnormality needs to be correlated with clinical change. Confluent white matter lesions show fast progression and correlations with cognitive decline. Thus, the change of confluent white matter lesions may be used as a surrogate marker in proof-of-concept trials with small patient numbers needed to show treatment effects on lesion progression. Nonetheless if the expected change in cognitive performance resulting from treatment effects on lesion progression is used as outcome, the sample size needed to show small to moderate treatment effects becomes very large. Lacunes may also fulfill the prerequisites of a surrogate marker, but in the general population the incidence of lacunes over short observational periods is small. For other small-vessel disease–related brain abnormalities including microbleeds and microstructural changes in normal-appearing white matter longitudinal change and correlations with clinical decline is not yet fully determined. Journal of Cerebral Blood Flow & Metabolism advance online publication, 22 April 2015; doi:10.1038/jcbfm.2015.72 Keywords: lacunes; microbleeds; normal-appearing brain tissue; small-vessel disease; white matter lesions

INTRODUCTION Cerebral small vessel disease is the second most common endemic entity of the aging brain following Alzheimer pathology. White matter lesions (WML), lacunar infarctions and cerebral microbleeds are the hallmark lesions of cerebral small vessel disease.1 They can be non-invasively depicted by brain magnetic resonance imaging. Figure 1 displays the spectrum of small vessel disease-related brain abnormalities. Up to 90% of patients above the age of 65 years present WMLs of varying severity when undergoing MRI.2 Lacunes occur less commonly with a frequency ranging from 6% to 20%,3 and microbleeds affect 5% to 15% of the general elderly population. Decreased mobility caused by disequilibrium and gait abnormalities, and progressive cognitive impairment up to dementia are frequent clinical sequelae of cerebral microangiopathy.1 An often neglected dysexecutive syndrome with slowing of mental processing, inhibition, and only mild memory impairment are the core cognitive dysfunctions. Because of the slow progressive course of these clinical correlates, symptoms remain often unnoticed in clinical evaluations. Nonetheless, they represent important causes of physical disability of older persons and thus are thought to have an enormous socioeconomic impact.4 Recent advances in imaging techniques have highlighted the importance of normal-appearing brain tissue in the context of age-related white matter abnormalities. In fact, these studies show that there is more widespread tissue damage associated with WMLs and possibly also other small-vessel disease–related lesion types that is not visible in conventional MR images. Such microstructural tissue abnormalities can be detected by new quantitative MR

techniques, such as diffusion tensor imaging (DTI) and magnetization transfer imaging (MTI).5,6 Microstructural changes in normal brain tissue have been shown to be more closely related to the patients’ clinical presentation than the volume of visible white matter abnormalities. Although the majority of data on the clinical effects of smallvessel disease–related brain abnormalities still come from crosssectional studies, numerous longitudinal MRI studies have meanwhile been conducted and increase our understanding of the natural history of cerebral small–vessel disease in general, and of differences in the evolution of related lesion types, in particular. Most importantly, there exists, not yet any, established treatment, which was proven to modify the evolution of smallvessel disease–related brain damage. Progression of small-vessel disease–related brain lesions has been suggested to facilitate treatment development by serving as secondary surrogate endpoints in clinical trials on subcortical vascular cognitive impairment. There are several prerequisites that need to be fulfilled for any MRI abnormality to be considered as a potential surrogate endpoint.7 These include (1) a reasonable confidence that the observed tissue changes are indeed related to cerebral microangiopathy; (2) evidence for a rate of progression, which is fast enough to allow monitoring of treatment effects within a reasonable period of time; and (3) a correlation between the change of the imaging marker with changes in clinical outcomes. In this review, we report the progression rate and clinical consequences of the different types of small-vessel disease– related brain abnormalities and provide sample size calculations for trial planning for each abnormality.

Department of Neurology, Medical University of Graz, Graz, Austria. Correspondence: Professor Dr R Schmidt, Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, Graz A-8036, Austria. E-mail: [email protected] Received 20 February 2015; accepted 16 March 2015

Change of small-vessel disease–related brain abnormalities R Schmidt et al

2

Figure 1. The spectrum of small-vessel disease–related brain changes in magnetic resonance imaging (MRI). White matter lesions ranging from punctuate foci to extensive confluent abnormalities (A, B, and C), cerebral microbleeds (D), and lacunar infarcts (E and F).

WHITE MATTER LESIONS Longitudinal studies8–26 showed considerable progression of WMLs within a period of few years (Table 1). There is almost no progression of punctate lesions on MRI, while early confluent and confluent abnormalities progress rapidly. In normally aging people with early confluent to confluent lesions, the mean rate of progression ranges from 0.23 to 1.33 cm3/year.25 A faster rate of progression was observed in people with arterial hypertension (0.14 to 0.54 cm3/year)27 and in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukencephalopathy patients (3.96 cm3/year).28 The annual increase in WML volume in percentage ranges between 12.5% and 14.4% in subjects with early confluent lesions and between 17.3% and 25.0% in those with confluent abnormalities.22 There is evidence that WMLs do not progress randomly. One recent study on 150 cognitively normal and demented people found that up to 80% of incident WMLs occurring over an observational period of 4 years represented extensions of preexisting lesions.29 In 365 patients with CADASIL and in 588 healthy elderly subjects from the Austrian Stroke Prevention Study, WMLs expanded from the periventricular white matter, where they were most prevalent, preferentially toward the subcortical white matter. They grew favorably along the trajectories of small perforating arteries, suggesting the vascular end zone as a predilection site for WMLs.30 Several studies reported that baseline WML grade is the strongest predictor of future progression of such changes,22,25,26,31 followed by arterial hypertension.9,26,32–34 Notably in the study by Verhaaren et al.,33 people with uncontrolled untreated hypertension had significantly more WML progression than people with uncontrolled, but treated hypertension.33 Similar results come from the Three-City (3C)Dijon Magnetic Resonance Imaging study. In a sample of 1,319 elderly individuals, antihypertensive treatment was related to a smaller increase in WML volume over a 4-year follow-up period.34 If blood pressure treatment influences WML progression sufficiently to slow down cognitive decline, has to be determined. Journal of Cerebral Blood Flow & Metabolism (2015), 1 – 8

Other, commonly reported risk factors for WML progression are higher age,26 previous stroke and diabetes,12 hyperhomocysteinemia,35 and the presence of the apolipoprotein E e4 allele.36 Genetic association studies in the setting of the Austrian Stroke Prevention Study described that polymorphisms in the renin–angiotensin system31 increased the susceptibility for progression of cerebral small–vessel disease 3.19-fold, independent of arterial hypertension. Also genetic variants of the paraoxonase gene, a gene important for antioxidative defense mechanisms,37 relate to WML progression. Recently, four single nucleotide polymorphisms within the neurogenic locus notch homolog protein 3 gene, that is responsible for CADASIL, were found to be associated with both the presence and progression of WMLs.38 White matter lesion progression has been associated with cognitive decline and dementia, incident stroke, gait dysfunction, and depression (Table 2). Longitudinal studies consistently reported a relationship between WML progression and decline in global as well as specific cognitive performance.10,18,23,24,26,29,39–45 In the Cardiovascular Health Study, increase in WML grades was related to global cognitive decline.24 In the Rotterdam Study, progression of periventricular WMLs was associated with decline in general cognitive performance and information processing speed.26 In the Austrian Stroke Prevention Study, we observed a complex interaction between increasing volume of WMLs, brain atrophy and cognition. Brain volume change mediated the association between WML progression and cognitive decline. This was seen for domains of memory, executive function, and visuopractical skills.39 Greater WML load at baseline predicts conversion from normal aging to mild cognitive impairment46 and conversion from amnestic mild cognitive impairment to Alzheimer's disease.47 This highlights the clinical importance of WMLs. In the Leukoaraiosis And DISability (LADIS) study, baseline WML load also predicted global functional decline and disability over a relatively short observational period of 2.42 years.48 In the Austrian Stroke Prevention Study, we estimated that ~ 200 individuals with confluent lesions would be necessary per © 2015 ISCBFM

Change of small-vessel disease–related brain abnormalities R Schmidt et al

3 Table 1.

Progression of WMLs in different longitudinal MRI studies

Study group

Year Sample

Wahlund et al.8 Veldink et al.9 Whitman et al.21 Schmidt et al.22 Taylor et al.10 ten Dam et al.11 Garde et al.23 Longstreth et al.24 Sachdev et al.25

1996 1998 2001 2003 2003 2005 2005 2005 2007

van Dijk et al.26

2008 Population based (RS)

12

Gouw et al.

Controls Controls and cognitively impaired Controls Community dwelling (ASPS) Community dwelling Trial cohort (PROSPER study) Octogenarians Population based (CHS) Community dwelling

Maillard et al. Gottesman et al.14

2008 Community dwelling (LADIS study) 2009 Population based (3 City study) 2010 Population based (ARIC)

Maillard et al.29 Lo et al.15

2012 Cohort study 2012 Cohort study (ADNI)

Maillard et al.16 Kaffashian et al.17 Peng et al.18 Erdélyi-Bótor et al.19

2013 2014 2014 2015

Brickman et al.20

2015 Washington Heights-Inwood Columbia Aging project; nondemented older adults

13

Progression rate (% patients; volume increase)

N

92% 57% 1.1 cm3 17.2%; 1.4 cm3 1.4 cm3 1.1 cm3 2.6 cm3 28% 6.5 cm3 PVWMLs 16.3 cm3 DWMLs 27% PVWMLs 32% DWMLs 74%

13 14 70 296 117 535 26 1,919 51

5 2 4 6 2 2.8 3.8 5 3

Scheltens scale Scheltens scale Grid method Semiautomated volume measurement Semiautomated volume measurement Automated volume measurement Semiautomated volume measurement CHS scoring Automated volume measurement

668

3.4

Modified Rotterdam Progression scale

396

3

Modified Rotterdam Progression scale

1,118 983

4 11 4 1.7–3

Automated volume measurement Estimated volume from a prediction equation from visual grades Semiautomated volume measurement Automated volume measurement

3.7 4 4 3

Semiautomated procedure Fully automated image processing software Automated subcortical segmentation routine 3D slicer

4.6

Semiautomated procedure

3

0.25 cm /year 13 cm3

Follow-up Progression measure (years)

2.5 cm3 150 MCI = 0.0076 cm3/month 819 3 AD = 0.0074 cm /month N = 0.0049 cm3/month 0.51 mL/year 119 n/s 1,057 29.31% Change over 4 years 294 67.7% Increased in size, 17 3.51% identical size, 23.3% decreased volume, and 33% new Frontal: 3.83 cm3, 303 temporal: 0.38 cm3, 3 parietal: 2.68 cm , and occipital: 0.80 cm3

Community dwelling Population-based 3C study Community dwelling Prospectively enrolled migraine patients with WHMs

Abbreviations: AD, Alzheimer's disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; ARIC, Atherosclerosis Risk in Communities; ASPS, Austrian Stroke Prevention Study; CHS, Cardiovascular Health Study; DWMLs, deep WMLs; LADIS, Leukoaraiosis And DISability study; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; N, number of subjects; n/s, not specified; PROSPER, PROspective Study of Pravastatin in the Elderly at Risk; PVWMLs, periventricular WMLs; RS, Rotterdam Study; WMHs, white matter hyperintensities; WMLs, white matter lesions.

Table 2.

Progression of WMLs and correlation with clinical outcome

Study

Sample

Garde et al.44 Schmidt et al.

39

Community-dwelling octogenarians Community dwelling (ASPS)

Longstreth et al.24 van den Heuvel et al.27 Kramer et al.40 van Dijk et al.26

Population based (CHS) Trial cohort Healthy elderly Population based (RS)

Silbert et al.41

Peng et al.18

Ongoing longitudinal study (Oregon Brain Aging study) Consecutive patients at the University of California, Davis Alzheimer’s Disease Center Patients with major depression Community dwelling (LADIS study) Population-based Mayo Clinic Study of Aging Community dwelling

Kloppenborg et al.43

Meta-analysis

Garde et al.23

Community-dwelling octogenarians

Maillard et al.29 Taylor et al.10 Firbank et al.45 Vemuri et al.42

N 26 243

Follow-up MRI findings (years)

Outcome

3.8

WML volume increase

Performance and verbal decline in WAIS

6

WML volume increase

5 3 3.7 3

Worsening WML grade Progression of PVWMLs WML progression PVWML progression

104

13

150

4

Incident MRI voxels

Decline in memory, conceptual reasoning and visuopractical skills Decline in MMSE and DSST Reduced mental processing speed Lower executive score at follow-up Decline in general cognitive function and in particular information processing speed Decreased gait performance and decreased performance on logical memory testing Decline in episodic memory and executive function

133

2 3

WML volume increase WML progression

Poor outcome (treatment response) Incident depression

393

2.7

294

4

Baseline vascular burden as predictor of cognition WML volume increase

Decreasing cognitive performance with increasing severity of pathologic changes Systolic blood pressure levels are associated with enhanced progression of cognitive decline and WMLs Baseline and progression of WMH load was associated with greater decline in attention and executive functions WML volume correlates with decline in verbal IQ

1,919 554 50 668

7,731 26

1.5–10 3.8

DWML volume increase

Baseline WML volume and progression of WMHs WML volume increase

Abbreviations: ASPS, Austrian Stroke Prevention Study; CHS, Cardiovascular Health Study; DSST, Digit Symbol Substitution Test; DWML, deep WML; LADIS, Leukoaraiosis And DISability study; MMSE, Mini-Mental State Examination; MRI, magnetic resonance imaging; N, number of subjects; PVWMLs, periventricular WMLs; RS, Rotterdam Study; WMHs, white matter hyperintensities; WAIS, Wechsler Adult Intelligence scale; WMLs, white matter lesions.

© 2015 ISCBFM

Journal of Cerebral Blood Flow & Metabolism (2015), 1 – 8

Change of small-vessel disease–related brain abnormalities R Schmidt et al

4 Table 3. Sample size estimates per treatment arm according to WML grade at baseline in a 3-year trial in which treatment reduces WML progression by one gradea Trial outcome measures

All WML grades

Early confluent and confluent WMLs

70 2,599 1,809

58 18,853 1,988

Reduction of WML progression (scenario 1) VADAS-Cog change (scenario 2) Executive function change (scenario 3)

Abbreviations: RPS, Rotterdam Progression scale; VADAS-Cog, Vascular Dementia Assessment Scale cognitive subscale; WML, white matter lesion. aAll calculations assumed a power of 80% at a two-sided significance level of 5%. Scenario 1: trial outcome is reduction of WML progression by one grade on the RPS; scenario 2: outcome is change in VADAS-Cog resulting from reduction of one grade in WML progression on the RPS; and scenario 3: outcome is change in executive functioning resulting from reduction of one grade in WML progression on the RPS.

Table 4.

Frequency of incident lacunes in different MRI studies

Study

Sample

Gouw et al.12 van Dijk et al.26 Longstreth et al.53 Giroud et al.54 Duering et al.30

Community dwelling (LADIS Study) Population based (RS) Population based (CHS) Stroke Registry of Dijon Two-center study (Klinikum Großhadern, ASPS)

N

Follow-up (years)

Frequency of new lacunes (%)

396 668 1,433 140,000 276

3 3.4 5 5 1.5–4.5

19 12 14.6 16.7 23.2

Abbreviations: ASPS, Austrian Stroke Prevention Study; CHS, Cardiovascular Health Study; LADIS, Leukoaraiosis And DISability study; MRI, magnetic resonance imaging; N, number of subjects; RS, Rotterdam Study.

treatment arm to show a 20% reduction in disease progression over a 3-year time period.7 Thus, WML progression became an interesting outcome measure for proof-of-concept studies in cerebral small–vessel disease. Owing to the fact that volumetric measurements of WML change are laborious and time consuming, a visual rating scale to assess progression might be better suited in clinical trials. A recent publication from the LADIS study evaluated the association between WML progression determined on the visual Rotterdam Progression scale49 and cognitive functioning, and provided sample size calculations for clinical trials using the Rotterdam Progression scale rated WML progression as surrogate endpoints.50 Progression was seen in 73.6% of the study participants. In line with previous studies,51 WML grade at baseline was the strongest predictor of future WML progression. Cognitive functions were assessed by the Vascular Dementia Assessment Scale cognitive subscale52 and by a composite score of specific executive function tests. Table 3 summarizes the results. As can be seen from Table 3, low subject numbers are required per treatment arm in scenario 1 trials in which WML progression is the primary outcome measure. Such settings will allow lowering sample sizes when including only individuals with early confluent or confluent lesions. For scenarios 2 and 3, in which the expected change in cognitive performance resulting from treatment effects on WML progression was the outcome, 2,599 or 18,853 subjects per treatment arm would be necessary for Vascular Dementia Assessment Scale cognitive subscale and 1,809 or 1,988 for the executive function test. These data underline that sample size strongly depends on both baseline WML grade and applied cognitive tests.50 The tremendously large sample sizes in a trial in patients with early confluent or confluent WMLs using Vascular Dementia Assessment Scale cognitive subscale as the clinical outcome was probably caused by a pronounced cognitive deterioration in individuals with early confluent and confluent WMLs irrespective of future lesion progression. Journal of Cerebral Blood Flow & Metabolism (2015), 1 – 8

LACUNES The incidence rates of lacunes over varying observational periods in various longitudinal studies are reported in Table 4.12,26,30,53,54 The frequency of new lacunes ranged from 1.6% to 19% over 3 to 5 years of follow-up.54 The largest study on incidence of lacunes was conducted in the setting of the Dijon Stroke Registry54 and included 140,000 participants. Giroud et al.54 reported an incidence rate of lacunes of 16.7% over 5 years. Similar rates are reported by the Rotterdam Scan Study,26 the Cardiovascular Health Study,24 and by the LADIS study.55 New evidence on the pathophysiology of lacunes was reported by Duering et al.30 In 365 CADASIL patients, 91.3% of incident lacunes appeared in brain regions showing contact or partial overlap with preexisting WMLs. Only 5.8% developed fully inside a preexisting WMLs and only 2.9% developed in the normalappearing white matter at baseline. Figure 2 shows a schematic of incidence of lacunes with regard to their vicinity to WMLs, proposed by Duering et al.30 Thus, tissue adjacent to WMLs might be especially susceptible to further ischemia including formation of lacunes. Such subtle changes in the white matter surrounding WMLs are detectable on DTI and have been described and termed ‘white matter hyperintentity penumbra’ by Maillard et al.56 Several cross-sectional studies found a relationship between the presence of lacunes and cognitive impairment. Only few longitudinal data on the relationship between incident lacunes and clinical outcomes are available (Table 5). Studies consistently show that incident lacunes exert detrimental functional effects. The Cardiovascular Health Study reports that the incidence of lacunes was related to decline in the MiniMental State Examination and the Digit Symbol Substitution Test.53 Similar associations were found in the Rotterdam Scan Study where incident lacunes were related to a decline in general cognitive function and information processing speed.26 In the LADIS study, a relationship between incident lacunes at 3-year follow-up and steeper decline in executive functions and psychomotor speed was reported.57 © 2015 ISCBFM

Change of small-vessel disease–related brain abnormalities R Schmidt et al

5 According to the previously published data on the rate of incident lacunes,12,26,30,53,54 detection of a 20% treatment effect in a 3-year trial with 80% power would require samples sizes in the range between 1,540 and 3,678 patients. MICROBLEEDS The Rotterdam Scan Study showed that the incidence of cerebral microbleeds strongly depends on age.58 The rate of lesions was reported to be 7.6% in subjects aged 60 to 69 years, it increased to 15.6% in the age range between 70 and 79 years, and 18.6% in subjects older 80 years. Subjects with microbleeds at baseline showed more than five times higher risk for newly occurring microbleeds as compared with their counterparts without such baseline abnormalities.59 In a smaller longitudinal study, which reassessed patients with stroke or transient ischemic attack after 412 months, 53.9% of the patients with cerebral microbleeds at baseline showed new microbleeds at follow-up.60

Figure 2. Incident lacunes and their location regarding preexisting white matter lesions (WMLs) according to Duering et al.30 Based on the rating, lacunes are classified as (A) grade 0: no contact with WMLs (2.9%), (B) grade Ia: contact with WMLs but no overlap (45.2%), (C) grade Ib: partial overlap (46.1%), and (D) grade II: complete overlap (5.8%). Table 5.

So far, little information exists on the clinical consequences of incident cerebral microbleeds. There are only a few longitudinal studies available.61–64 Although Gregoire et al.64 report on the predictive value of baseline microbleeds considering executive functions over 5.7 years, Meier et al.62 report on decreasing executive functions if at least two microbleeds are present. Liem et al.61 identified increasing cognitive decline with increasing number of incident microbleeds in CADASIL patients over 7 years of follow-up. Moreover, patients with warfarin therapy and baseline microbleeds had an increased risk for additional microbleeds.63 Because of the lack of clinical correlative data the validation status of these lesions as a possible surrogate marker in vascular cognitive impairment trials has to be considered incomplete and sample size calculations are thus not provided. MICROSTRUCTURAL CHANGES IN NORMAL-APPEARING BRAIN TISSUE Recent advances in imaging techniques have highlighted the importance of normal-appearing brain tissue in the context of WMLs. There is more widespread tissue damage associated with WMLs, which is not visible in conventional MRI but can be detected by DTI and MTI.5,6 Diffusion tensor imaging provides information about the microstructural integrity of brain tissue by measuring the direction and magnitude of water diffusion in the intracellular compartment of the axons. Because of the restriction by lipid bilayers and other cell components, water diffusion in brain tissue is anisotropic with the highest diffusivity along the directions of the axons. MTI is an approach to explore the composition of brain tissue. Protons bound to macromolecules such as the myelin lipids and proteins have relaxation properties that make them invisible for conventional MRI. However, the pool of bound protons can be imaged indirectly by exploiting magnetization transfer. Animal models and postmortem studies indicate that quantitative DTI and MTI measures correlate with markers of myelin integrity, and axonal damage and density.65–68 A study in brain hypoperfused mice examined the complementary value of DTI and MTI measures for delineation of white matter damage.68 After continuous moderate hypoperfusion over 1 month the authors found that the reduction in fractional anisotropy paralleled a decrease in magnetization transfer ratio in several tissue compartments. They concluded that both techniques are adequately suited to detect microstructural tissue alterations at least in the white matter of the murine brain. Postmortem histopathologic analyses assessing myelin content, axonal density, and gliosis revealed similar correlations in the brains of patients with Alzheimer’s disease65 and multiple sclerosis.69 There is evidence that normal-appearing white matter magnetization transfer ratio decreases with increasing WML burden and magnetization transfer ratio within WMLs is on average ~ 10% lower than that of normal-appearing white matter, indicating microstructural tissue damage within and outside WMLs.70,71 Similar observations have been made using DTI. Important in this context, the prognostic value of baseline local DTI parameters for WML progression within a 4-year period has been reported.72

Incident lacunes and correlation with clinical outcome in longitudinal studies

Study

Sample

Longstreth et al.53 van Dijk et al.26

Population based (CHS) Population based (RS)

Jokinen et al.

57

Community dwelling (LADIS study)

N

Follow-up (years)

1,433 668

5 3

387

3

Outcome Decline in MMSE and DSST Decline in general cognitive function, in particular information processing speed Decline in executive function and psychomotor speed

Abbreviations: CHS, Cardiovascular Health Study; DSST, Digit Symbol Substitution Test; LADIS, Leukoaraiosis And DISability study; MMSE, Mini-Mental State Examination; N, number of subjects; RS, Rotterdam Study.

© 2015 ISCBFM

Journal of Cerebral Blood Flow & Metabolism (2015), 1 – 8

Change of small-vessel disease–related brain abnormalities R Schmidt et al

6 Table 6.

Longitudinal microstructural changes

Study group

Year Sample

Holtmannspötter et al.28 2005 CADASIL 2010 Healthy middle versus Barrick et al.86 older-aged subjects Charlton et al.87 Sullivan et al.88 Maillard et al.16 Sexton et al.89 Auriel et al.73 Maniega et al.90

2010 Healthy middle versus older-aged subjects 2010 Younger versus elderly healthy subjects 2013 Healthy elderly, AD and MCI patients 2014 Healthy elderly 2014 Subjects with CAA (asymptomatic infarctions) 2014 Older subjects

N

Results MD correlates with clinical measures Significant change in WM integrity throughout the brain (no evidence for accelerated decline in any brain area) Decreasing FA and increasing MD Decreasing FA, increased ADC, and increasing DA and RD Lower baseline FA has a higher risk to convert from NAWM to WMH Annual decrease in FA and increase in DA, RD, and MD; accelerated annual change with ageing, especially in fifth decade Decreased FA and increased MD in lesions WMHs have reduced WM integrity compared with NAWM

Follow-up Measure (years)

73

2.2 2

MD FA, DA, and RD

84

2

FA and MD

16

2

FA, ADC, DA, and RD FA

119

3.7

203

3.6

FA, DA, RD, and MD

2

FA and MD

6 676

n/s

FA, MD, and MTR

Abbreviations: AD, Alzheimer's disease; ADC, apparent diffusion coefficient; CAA, cerebral amyloid angiopathy; CADSIL, Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy; DA, axial diffusivity; FA, fractional anisotropy; MCI, mild cognitive impairment; MD, mean diffusivity; MTR, magnetization transfer ratio; NAWM, normal-appearing white matter; n/s, not specified; RD, radial diffusivity; WM, white matter; WMHs, WM hyperintensities.

So far, there have been only a few studies assessing the association between microstructural tissue alterations and cerebral vascular changes. A recent longitudinal study showed an association between small asymptomatic diffusion–weighted imaging hyperintense lesions and microstructural alterations and linked these results to vascular cognitive impairment.73 Further, correlations of diffusion parameters in patients with small-vessel disease and cognitive outcome measures (e.g., memory, psychomotor speed, concept shifting, and attention) were also found to be significant.74–77 Table 6 gives an overview of longitudinal studies reporting sensitivity of the measures in normal-appearing brain tissue in younger, middle, and olderaged elderly subjects. A multimodal study evaluating MRI parameters as surrogate markers of cerebral small–vessel disease reported a 1.18% decrease in peak height of mean diffusivity and a 10.73% increase in fractional anisotropy in patients with lacunar stroke and leukoaraiosis over 1 year despite unchanged lesion load and brain volume.78 Diffusion tensor imaging changes correlate more closely to cognitive functioning than the volume of visible small-vessel disease–related changes such as WMLs. So far, only few longitudinal studies on the relationship between increase of microstructural damage and cognitive decline are available. We know even less about the relationship between longitudinal MTI measures and cognition. Results from the LADIS study showed that microstructural changes, detected with diffusion weighted imaging in normal appearing brain tissue, predict faster decline in cognitive parameters.79 In a longitudinal study, in 62 CADASIL subjects the changes in mean diffusivity correlated with changes in the Rankin score, national institute of health stroke scale and structured interview for the diagnosis of dementia of the Alzheimer type, multiinfarct dementia and dementias of other aetiology within a 2-year observation period.28 Diffusion tensor imaging was also used in early detection80,81 and monitoring of disease progression from mild cognitive impairment to Alzheimer's disease.82 Sample size calculation based on 2-year follow-up data in CADASIL patients showed that one would need 1,944 subjects per treatment arm to show a treatment effect of 20% with an 80% power when mean diffusivity is used as the trial outcome.28 Journal of Cerebral Blood Flow & Metabolism (2015), 1 – 8

CONCLUSIONS Presently, only confluent WMLs are MRI correlates of cerebral SVD for which a vascular origin, fast progression, and relation to cognitive decline has been established. Lacunes may fulfill these prerequisites in selective patient samples but in the general population the occurrence of new lacunes over short time periods is rather small and sample size in trials focusing on lacunes would therefore need to be large. In line with current data, confluent WMLs are ideal surrogate markers in proof-of-concept studies in patients with subcortical vascular cognitive impairment. However, if such trials aim to show slowing of cognitive decline resulting from treatment effects on WML progression, sample sizes will need to increase remarkably. Up to now, only few proof-ofconcept studies on vascular cognitive impairment have included WMLs. The effect of antihypertensive therapy and statin use on WML progression was evaluated in the PROspective Study of Pravastatin in the Elderly at Risk study and in the Perindopril Protection Against Recurrent Stroke Study.11,83 The MRI substudy of PROspective Study of Pravastatin in the Elderly at Risk assessed the influence of daily therapy with pravastatin on the progression of ischemic brain lesions, including WMLs. After a mean time period of 33 months, there was no difference in progression of WML volume between the 265 participants in the treatment group versus the 270 participants in the placebo arm. Perindopril Protection Against Recurrent Stroke Study examined whether blood pressure lowering therapy with perindopril and indapamide reduces the progression of WMLs in patients with cerebrovascular disease. The study included 192 individuals who had cerebral MRI at baseline and after 36 months. The authors found that an active blood pressure–lowering regimen stopped or delayed the progression of WMLs. Recent data from the Vitamins To Prevent Stroke study showed that daily B-vitamin supplementation for 2 years did not significantly reduce the progression of WML volume in a sample of 359 patients with recent stroke or transient ischemic attack and cerebral SVD, but may do so in the subgroup of patients with severe cerebral SVD.84 These studies provide important first evidence for possible treatment strategies in cerebral SVD, which is still a severely understudied disorder with important implications on the functional status of our aging population. The perspective of new treatment targets originating from recent © 2015 ISCBFM

Change of small-vessel disease–related brain abnormalities R Schmidt et al

genetic association studies85 underscores the importance of having validated surrogate markers, which will allow to conduct proof-of-concept studies in a timely manner at relatively low cost. DISCLOSURE/CONFLICT OF INTEREST The authors declare no conflict of interest.

REFERENCES 1 Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9: 689–701. 2 Schmidt R, Schmidt H, Haybaeck J, Loitfelder M, Weis S, Cavalieri M et al. Heterogeneity in age-related white matter changes. Acta Neuropathol 2011; 122: 171–185. 3 Cavalieri M, Schmidt H, Schmidt R. Structural MRI in normal aging and Alzheimer’s disease: white and black spots. Neurodegener Dis 2012; 10: 253–256. 4 Poggesi A, Pantoni L, Inzitari D, Fazekas F, Ferro J, O'Brien J et al. The LADIS Study Group 2001–2011: a decade of the LADIS (Leukoaraiosis And DISability) Study: what have we learned about white matter changes and small-vessel disease?. Cerebrovasc Dis 2011; 32: 577–588. 5 Graham SJ, Henkelman RM. Understanding pulsed magnetization transfer. J Magn Reson Imaging 1997; 7: 903–912. 6 Mori S, Zhang J. Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron 2006; 51: 527–539. 7 Schmidt R, Scheltens P, Erkinjuntti T, Pantoni L, Markus HS, Wallin A et al. White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. Neurology 2004; 63: 139–144. 8 Wahlund LO, Almkvist O, Basun H, Julin P. MRI in successful aging, a 5-year followup study from the eighth to ninth decade of life. Magn Reson Imaging 1996; 14: 601–608. 9 Veldink JH, Scheltens P, Jonker C, Launer LJ. Progression of cerebral white matter hyperintensities on MRI is related to diastolic blood pressure. Neurology 1998; 51: 319–320. 10 Taylor WD, MacFall JR, Provenzale JM, Payne ME, McQuoid DR, Steffens DC et al. Serial MR imaging of volumes of hyperintense white matter lesions in elderly patients: correlation with vascular risk factors. AJR Am J Roentgenol 2003; 181: 571–576. 11 ten Dam VH, van den Heuvel DMJ, van Buchem MA, Westendorp RGJ, Bollen ELEM, Ford I et al. Effect of pravastatin on cerebral infarcts and white matter lesions. Neurology 2005; 64: 1807–1809. 12 Gouw AA, van der Flier WM, Fazekas F, van Straaten ECW, Pantoni L, Poggesi A et al. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke 2008; 39: 1414–1420. 13 Maillard P, Crivello F, Dufouil C, Tzourio-Mazoyer N, Tzourio C, Mazoyer B. Longitudinal follow-up of individual white matter hyperintensities in a large cohort of elderly. Neuroradiology 2009; 51: 209–220. 14 Gottesman RF, Coresh J, Catellier DJ, Sharrett AR, Rose KM, Coker LH et al. Blood pressure and white-matter disease progression in a biethnic cohort: Atherosclerosis Risk in Communities (ARIC) study. Stroke 2010; 41: 3–8. 15 Lo RY, Jagust WJ. Vascular burden and Alzheimer disease pathologic progression. Neurology 2012; 79: 1349–1355. 16 Maillard P, Carmichael O, Harvey D, Fletcher E, Reed B, Mungas D et al. FLAIR and diffusion MRI signals are independent predictors of white matter hyperintensities. AJNR Am J Neuroradiol 2013; 34: 54–61. 17 Kaffashian S, Tzourio C, Soumaré A, Dufouil C, Zhu Y, Crivello F et al. Plasma β-amyloid and MRI markers of cerebral small vessel disease: Three-City Dijon study. Neurology 2014; 83: 2038–2045. 18 Peng J, Lu F, Wang Z, Zhong M, Sun L, Hu N et al. Excessive lowering of blood pressure is not beneficial for progression of brain white matter hyperintensive and cognitive impairment in elderly hypertensive patients: 4-year follow-up study. J Am Med Dir Assoc 2014; 15: 904–910. 19 Erdélyi-Bótor S, Aradi M, Kamson DO, Kovács N, Perlaki G, Orsi G et al. Changes of migraine-related white matter hyperintensities after 3 years: a longitudinal MRI study. Headache 2015; 55: 55–70. 20 Brickman AM, Zahodne LB, Guzman VA, Narkhede A, Meier IB, Griffith EY et al. Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer’s disease incidence. Neurobiol Aging 2015; 36: 27–32. 21 Whitman GT, Tang Y, Lin A, Baloh RW, Tang T. A prospective study of cerebral white matter abnormalities in older people with gait dysfunction. Neurology 2001; 57: 990–994.

© 2015 ISCBFM

7 22 Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet 2003; 361: 2046–2048. 23 Garde E, Lykke Mortensen E, Rostrup E, Paulson OB. Decline in intelligence is associated with progression in white matter hyperintensity volume. J Neurol Neurosurg Psychiatry 2005; 76: 1289–1291. 24 Longstreth WT, Arnold AM, Beauchamp NJ, Manolio TA, Lefkowitz D, Jungreis C et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2005; 36: 56–61. 25 Sachdev P, Wen W, Chen X, Brodaty H. Progression of white matter hyperintensities in elderly individuals over 3 years. Neurology 2007; 68: 214–222. 26 van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MMB. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke 2008; 39: 2712–2719. 27 van den Heuvel DMJ, ten Dam VH, de Craen AJM, Admiraal-Behloul F, Olofsen H, Bollen ELEM et al. Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population. J Neurol Neurosurg Psychiatry 2006; 77: 149–153. 28 Holtmannspötter M, Peters N, Opherk C, Martin D, Herzog J, Brückmann H et al. Diffusion magnetic resonance histograms as a surrogate marker and predictor of disease progression in CADASIL: a two-year follow-up study. Stroke 2005; 36: 2559–2565. 29 Maillard P, Carmichael O, Fletcher E, Reed B, Mungas D, De Carli C. Coevolution of white matter hyperintensities and cognition in the elderly. Neurology 2012; 79: 442–448. 30 Duering M, Csanadi E, Gesierich B, Jouvent E, Hervé D, Seiler S et al. Incident lacunes preferentially localize to the edge of white matter hyperintensities: insights into the pathophysiology of cerebral small vessel disease. Brain 2013; 136: 2717–2726. 31 Schmidt R, Fazekas F, Enzinger C, Ropele S, Kapeller P, Schmidt H. Risk factors and progression of small vessel disease-related cerebral abnormalities. J Neural Transm Suppl 2002; (62): 47–52. 32 Schmidt R, Fazekas F, Kapeller P, Schmidt H, Hartung HP. MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study. Neurology 1999; 53: 132–139. 33 Verhaaren BFJ, Vernooij MW, de Boer R, Hofman A, Niessen WJ, van der Lugt A et al. High blood pressure and cerebral white matter lesion progression in the general population. Hypertension 2013; 61: 1354–1359. 34 Godin O, Tzourio C, Maillard P, Mazoyer B, Dufouil C. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)-Dijon Magnetic Resonance Imaging Study. Circulation 2011; 123: 266–273. 35 Kloppenborg RP, Geerlings MI, Visseren FL, Mali WPTM, Vermeulen M, van der Graaf Y et al. Homocysteine and progression of generalized small-vessel disease: the SMART-MR Study. Neurology 2014; 82: 777–783. 36 Godin O, Tzourio C, Maillard P, Alpérovitch A, Mazoyer B, Dufouil C. Apolipoprotein E genotype is related to progression of white matter lesion load. Stroke 2009; 40: 3186–3190. 37 Schmidt R, Schmidt H, Fazekas F, Kapeller P, Roob G, Lechner A et al. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms : three-year followup of the austrian stroke prevention study. Arterioscler Thromb Vasc Biol 2000; 20: 1811–1816. 38 Schmidt H, Zeginigg M, Wiltgen M, Freudenberger P, Petrovic K, Cavalieri M et al. Genetic variants of the NOTCH3 gene in the elderly and magnetic resonance imaging correlates of age-related cerebral small vessel disease. Brain 2011; 134: 3384–3397. 39 Schmidt R, Ropele S, Enzinger C, Petrovic K, Smith S, Schmidt H et al. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian stroke prevention study. Ann Neurol 2005; 58: 610–616. 40 Kramer JH, Mungas D, Reed BR, Wetzel ME, Burnett MM, Miller BL et al. Longitudinal MRI and cognitive change in healthy elderly. Neuropsychology 2007; 21: 412–418. 41 Silbert LC, Nelson C, Howieson DB, Moore MM, Kaye JA. Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline. Neurology 2008; 71: 108–113. 42 Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Preboske GM, Kantarci K et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain 2015; 138: 761–771. 43 Kloppenborg RP, Nederkoorn PJ. Presence and progression of white matter hyperintensities and cognition: a meta analysis. Neurology 2014; 82: 2127–2138. 44 Garde E, Mortensen EL, Krabbe K, Rostrup E, Larsson HB. Relation between agerelated decline in intelligence and cerebral white-matter hyperintensities in healthy octogenarians: a longitudinal study. Lancet 2000; 356: 628–634.

Journal of Cerebral Blood Flow & Metabolism (2015), 1 – 8

Change of small-vessel disease–related brain abnormalities R Schmidt et al

8 45 Firbank MJ, Teodorczuk A, van der Flier WM, Gouw AA, Wallin A, Erkinjuntti T et al. Relationship between progression of brain white matter changes and late-life depression: 3-year results from the LADIS study. Br J Psychiatry 2012; 201: 40–45. 46 Smith EE, Egorova S, Blacker D, Killiany RJ, Muzikansky A, Dickerson BC et al. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol 2008; 65: 94–100. 47 Van Straaten ECW, Harvey D, Scheltens P, Barkhof F, Petersen RC, Thal LJ et al. Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. J Neurol 2008; 255: 1302–1308. 48 Inzitari D, Pracucci G, Poggesi A, Carlucci G, Barkhof F, Chabriat H et al. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. BMJ 2009; 339: b2477. 49 Prins ND, van Straaten ECW, van Dijk EJ, Simoni M, van Schijndel RA, Vrooman HA et al. Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics. Neurology 2004; 62: 1533–1539. 50 Schmidt R, Berghold A, Jokinen H, Gouw AA, van der Flier WM, Barkhof F et al. White matter lesion progression in LADIS: frequency, clinical effects, and sample size calculations. Stroke 2012; 43: 2643–2647. 51 Schmidt R, Petrovic K, Ropele S, Enzinger C, Fazekas F. Progression of leukoaraiosis and cognition. Stroke 2007; 38: 2619–2625. 52 Ferris SH. General measures of cognition. Int Psychogeriatr 2003; 15(Suppl 1): 215–217. 53 Longstreth WT Jr., Dulberg C, Manolio TA, Lewis MR, Beauchamp NJ Jr., O'Leary D et al. Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2002; 33: 2376–2382. 54 Giroud M, Milan C, Beuriat P, Gras P, Essayagh E, Arveux P et al. Incidence and survival rates during a two-year period of intracerebral and subarachnoid haemorrhages, cortical infarcts, lacunes and transient ischaemic attacks. The Stroke Registry of Dijon: 1985-1989. Int J Epidemiol 1991; 20: 892–899. 55 Gouw AA, van der Flier WM, Pantoni L, Inzitari D, Erkinjuntti T, Wahlund LO et al. On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. Stroke 2008; 39: 3083–3085. 56 Maillard P, Fletcher E, Harvey D, Carmichael O, Reed B, Mungas D et al. White matter hyperintensity penumbra. Stroke 2011; 42: 1917–1922. 57 Jokinen H, Gouw AA, Madureira S, Ylikoski R, van Straaten ECW, van der Flier WM et al. Incident lacunes influence cognitive decline: the LADIS study. Neurology 2011; 76: 1872–1878. 58 Poels MMF, Vernooij MW, Ikram MA, Hofman A, Krestin GP, van der Lugt A et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke 2010; 41: 103–106. 59 Poels MMF, Ikram MA, van der Lugt A, Hofman A, Krestin GP, Breteler MMB et al. Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study. Stroke 2011; 42: 656–661. 60 Lee S-H, Lee S-T, Kim BJ, Park H-K, Kim C-K, Jung K-H et al. Dynamic temporal change of cerebral microbleeds: long-term follow-up MRI study. PLoS One 2011; 6: e25930. 61 Liem MK, Haan J, Van Der Neut IL, Ferrari MD, Van Buchem MA, Van Der Grond J. MRI correlates of cognitive decline in CADASIL. Neurology 2009; 72: 143–148. 62 Meier IB, Gu Y, Guzaman VA, Wiegman AF, Schupf N, Manly JJ et al. Lobar microbleeds are associated with a decline in executive functioning in older adults. Cerebrovasc Dis 2014; 38: 377–383. 63 Orken DN, Uysal E, Timer E, Kuloglu-Pazarcı N, Mumcu S, Forta H. New cerebral microbleeds in ischemic stroke patients on warfarin treatment: two-year follow-up. Clin Neurol Neurosurg 2013; 115: 1682–1685. 64 Gregoire SM, Smith K, Jäger HR, Benjamin M, Kallis C, Brown MM et al. Cerebral microbleeds and long-term cognitive outcome: longitudinal cohort study of stroke clinic patients. Cerebrovasc Dis 2012; 33: 430–435. 65 Gouw AA, Seewann A, Vrenken H, van der Flier WM, Rozemuller JM, Barkhof F et al. Heterogeneity of white matter hyperintensities in Alzheimer’s disease: postmortem quantitative MRI and neuropathology. Brain 2008; 131: 3286–3298. 66 Schmierer K, Altmann DR, Kassim N, Kitzler H, Kerskens CM, Doege CA et al. Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study. Mult Scler 2004; 10: 182–187. 67 Shereen A, Nemkul N, Yang D, Adhami F, Dunn RS, Hazen ML et al. Ex vivo diffusion tensor imaging and neuropathological correlation in a murine model of hypoxia-ischemia-induced thrombotic stroke. J Cereb Blood Flow Metab 2011; 31: 1155–1169. 68 Holland PR, Bastin ME, Jansen MA, Merrifield GD, Coltman RB, Scott F et al. MRI is a sensitive marker of subtle white matter pathology in hypoperfused mice. Neurobiol Aging 2011; 32: 2325.e1–6.

Journal of Cerebral Blood Flow & Metabolism (2015), 1 – 8

69 Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004; 56: 407–415. 70 Fazekas F, Ropele S, Enzinger C, Gorani F, Seewann A, Petrovic K et al. MTI of white matter hyperintensities. Brain 2005; 128: 2926–2932. 71 Ropele S, Enzinger C, Söllinger M, Langkammer C, Wallner-Blazek M, Schmidt R et al. The impact of sex and vascular risk factors on brain tissue changes with aging: magnetization transfer imaging results of the Austrian stroke prevention study. AJNR Am J Neuroradiol 2010; 31: 1297–1301. 72 Cavallari M, Moscufo N, Meier D, Skudlarski P, Pearlson GD, White WB et al. Thalamic fractional anisotropy predicts accrual of cerebral white matter damage in older subjects with small-vessel disease. J Cereb Blood Flow Metab 2014; 34: 1321–1327. 73 Auriel E, Edlow BL, Reijmer YD, Fotiadis P, Ramirez-Martinez S, Ni J et al. Microinfarct disruption of white matter structure: a longitudinal diffusion tensor analysis. Neurology 2014; 83: 182–188. 74 Van Norden AGW, de Laat KF, van Dijk EJ, van Uden IWM, van Oudheusden LJB, Gons RAR et al. Diffusion tensor imaging and cognition in cerebral small vessel disease: the RUN DMC study. Biochim Biophys Acta 2012; 1822: 401–407. 75 Van der Holst HM, Tuladhar AM, van Norden AGW, de Laat KF, van Uden IWM, van Oudheusden LJB et al. Microstructural integrity of the cingulum is related to verbal memory performance in elderly with cerebral small vessel disease: the RUN DMC study. Neuroimage 2013; 65: 416–423. 76 Lawrence AJ, Patel B, Morris RG, MacKinnon AD, Rich PM, Barrick TR et al. Mechanisms of cognitive impairment in cerebral small vessel disease: multimodal MRI results from the St George’s cognition and neuroimaging in stroke (SCANS) study. PLoS One 2013; 8: e61014. 77 Cavallari M, Ceccarelli A, Wang G-Y, Moscufo N, Hannoun S, Matulis CR et al. Microstructural changes in the striatum and their impact on motor and neuropsychological performance in patients with multiple sclerosis. PLoS One 2014; 9: e101199. 78 Nitkunan A, Barrick TR, Charlton RA, Clark CA, Markus HS. Multimodal MRI in cerebral small vessel disease: its relationship with cognition and sensitivity to change over time. Stroke 2008; 39: 1999–2005. 79 Jokinen H, Schmidt R, Ropele S, Fazekas F, Gouw AA, Barkhof F et al. Diffusion changes predict cognitive and functional outcome. The LADIS Study. Ann Neurol 2013; 73: 576–583. 80 Hong YJ, Yoon B, Lim S-C, Shim YS, Kim J-Y, Ahn KJ et al. Microstructural changes in the hippocampus and posterior cingulate in mild cognitive impairment and Alzheimer’s disease: a diffusion tensor imaging study. Neurol Sci 2013; 34: 1215–1221. 81 Teipel SJ, Meindl T, Wagner M, Stieltjes B, Reuter S, Hauenstein K-H et al. Longitudinal changes in fiber tract integrity in healthy aging and mild cognitive impairment: a DTI follow-up study. J Alzheimers Dis 2010; 22: 507–522. 82 Chua TC, Wen W, Slavin MJ, Sachdev PS. Diffusion tensor imaging in mild cognitive impairment and Alzheimer’s disease: a review. Curr Opin Neurol 2008; 21: 83–92. 83 Dufouil C, Chalmers J, Coskun O, Besançon V, Bousser M-G, Guillon P et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112: 1644–1650. 84 Cavalieri M, Schmidt R, Chen C, Mok V, de Freitas GR, Song S et al. B Vitamins and MRI-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: The VITAmins TO Prevent Stroke (VITATOPS) MRI-Substudy. Stroke 2012; 43: 3266–3270. 85 Fornage M, Debette S, Bis JC, Schmidt H, Ikram MA, Dufouil C et al. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol 2011; 69: 928–939. 86 Barrick TR, Charlton RA, Clark CA, Markus HS. White matter structural decline in normal ageing: a prospective longitudinal study using tract-based spatial statistics. Neuroimage 2010; 51: 565–577. 87 Charlton RA, Schiavone F, Barrick TR, Morris RG, Markus HS. Diffusion tensor imaging detects age related white matter change over a 2 year follow-up which is associated with working memory decline. J Neurol Neurosurg Psychiatry 2010; 81: 13–19. 88 Sullivan EV, Rohlfing T, Pfefferbaum A. Longitudinal study of callosal microstructure in the normal adult aging brain using quantitative DTI fiber tracking. Dev Neuropsychol 2010; 35: 233–256. 89 Sexton CE, Walhovd KB, Storsve AB, Tamnes CK, Westlye LT, Johansen-Berg H et al. Accelerated changes in white matter microstructure during aging: a longitudinal diffusion tensor imaging study. J Neurosci 2014; 34: 15425–15436. 90 Maniega SM, Valdés Hernández MC, Clayden JD, Royle NA, Murray C, Morris Z et al. White matter hyperintensities and normal-appearing white matter integrity in the aging brain. Neurobiol Aging 2015; 36: 909–918.

© 2015 ISCBFM

Longitudinal change of small-vessel disease-related brain abnormalities.

Knowledge about the longitudinal change of cerebral small-vessel disease–related magnetic resonance imaging abnormalities increases our pathophysiolog...
672KB Sizes 0 Downloads 9 Views